Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 3
1999 1
2000 4
2002 2
2005 2
2006 1
2007 1
2008 5
2009 1
2010 3
2011 5
2012 3
2013 1
2014 3
2015 6
2016 4
2017 4
2018 4
2020 3
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Barbour T, et al. Kidney Int Rep. 2021 Mar 24;6(6):1603-1613. doi: 10.1016/j.ekir.2021.03.884. eCollection 2021 Jun. Kidney Int Rep. 2021. PMID: 34169200 Free PMC article.
Donor Cancer Transmission in Kidney Transplantation.
Baudoux TER, Gastaldello K, Rorive S, Hamade A, Broeders N, Nortier JL. Baudoux TER, et al. Among authors: broeders n. Kidney Int Rep. 2016 Sep 29;2(2):134-137. doi: 10.1016/j.ekir.2016.09.057. eCollection 2017 Mar. Kidney Int Rep. 2016. PMID: 29318211 Free PMC article. No abstract available.
Genome-Wide Association Study of Acute Renal Graft Rejection.
Ghisdal L, Baron C, Lebranchu Y, Viklický O, Konarikova A, Naesens M, Kuypers D, Dinic M, Alamartine E, Touchard G, Antoine T, Essig M, Rerolle JP, Merville P, Taupin JL, Le Meur Y, Grall-Jezequel A, Glowacki F, Noël C, Legendre C, Anglicheau D, Broeders N, Coppieters W, Docampo E, Georges M, Ajarchouh Z, Massart A, Racapé J, Abramowicz D, Abramowicz M. Ghisdal L, et al. Among authors: broeders n. Am J Transplant. 2017 Jan;17(1):201-209. doi: 10.1111/ajt.13912. Epub 2016 Jul 22. Am J Transplant. 2017. PMID: 27272414 Free PMC article.
[Mycophenolate mofetil].
Abramowicz D, Broeders N, Wissing M, Sternon J. Abramowicz D, et al. Among authors: broeders n. Rev Med Brux. 1998 Jun;19(3):139-43. Rev Med Brux. 1998. PMID: 9697397 French.
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2021 May;99(5):1244. doi: 10.1016/j.kint.2021.03.008. Kidney Int. 2021. PMID: 33892867 No abstract available.
49 results